Logo

Scynexis Reports Results of Brexafemme (Ibrexafungerp) in P-III VANISH-306 Study for Vaginal Yeast Infection

Share this
Scynexis Reports Results of Brexafemme (Ibrexafungerp) in P-III VANISH-306 Study for Vaginal Yeast Infection

Scynexis Reports Results of Brexafemme (Ibrexafungerp) in P-III VANISH-306 Study for Vaginal Yeast Infection

Shots:

  • The P-III VANISH-306 study evaluates ibrexafungerp vs PBO in women aged ≥12yrs. with VVC. The results were published in the International Journal of Obstetrics and Gynaecology (BJOG)
  • The 1EPs & 2EPs of the study showed that the patients treated with ibrexafungerp had higher rates of clinical cure (63.3% vs. 44.0%). The results also showed higher rates in mycological eradication (58.5% vs 29.8%) @10Day, and clinical improvement (72.3% vs. 54.8%). The therapy was generally well-tolerated
  • Additionally, the therapy showed a sustained symptom resolution @25 days (73.9% vs 52.4%) & complete symptom resolution in patients with C. Albicans at baseline (77.0% vs 52.6%), respectively

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Scynexis


Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions